Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

195 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T, Borchert S, Wessolly M, Mathilakathu A, Mairinger E, Kollmeier J, Mairinger T, Hegedus B, Greimelmaier K, Wohlschlaeger J, Herrmann K, Mairinger FD. Hager T, et al. Among authors: hegedus b. Int J Mol Sci. 2023 Mar 28;24(7):6356. doi: 10.3390/ijms24076356. Int J Mol Sci. 2023. PMID: 37047331 Free PMC article.
Screening of Pleural Mesothelioma Cell Lines for Kinase Activity May Identify New Mechanisms of Therapy Resistance in Patients Receiving Platin-Based Chemotherapy.
Borchert S, Suckrau PM, Wessolly M, Mairinger E, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Walter RFH, Mairinger FD. Borchert S, et al. Among authors: hegedus b. J Oncol. 2019 Dec 23;2019:2902985. doi: 10.1155/2019/2902985. eCollection 2019. J Oncol. 2019. PMID: 31929796 Free PMC article.
Tumour cell PD-L1 expression is prognostic in patients with malignant pleural effusion: the impact of C-reactive protein and immune-checkpoint inhibition.
Ghanim B, Rosenmayr A, Stockhammer P, Vogl M, Celik A, Bas A, Kurul IC, Akyurek N, Varga A, Plönes T, Bankfalvi A, Hager T, Schuler M, Hackner K, Errhalt P, Scheed A, Seebacher G, Hegedus B, Stubenberger E, Aigner C. Ghanim B, et al. Among authors: hegedus b. Sci Rep. 2020 Apr 1;10(1):5784. doi: 10.1038/s41598-020-62813-2. Sci Rep. 2020. PMID: 32238865 Free PMC article.
HDAC Inhibition Induces PD-L1 Expression in a Novel Anaplastic Thyroid Cancer Cell Line.
Hegedűs L, Rittler D, Garay T, Stockhammer P, Kovács I, Döme B, Theurer S, Hager T, Herold T, Kalbourtzis S, Bankfalvi A, Schmid KW, Führer D, Aigner C, Hegedűs B. Hegedűs L, et al. Among authors: hegedus b. Pathol Oncol Res. 2020 Oct;26(4):2523-2535. doi: 10.1007/s12253-020-00834-y. Epub 2020 Jun 26. Pathol Oncol Res. 2020. PMID: 32591993 Free PMC article.
Impact of metallothionein-knockdown on cisplatin resistance in malignant pleural mesothelioma.
Borchert S, Suckrau PM, Walter RFH, Wessolly M, Mairinger E, Steinborn J, Hegedus B, Hager T, Herold T, Eberhardt WEE, Wohlschlaeger J, Aigner C, Bankfalvi A, Schmid KW, Mairinger FD. Borchert S, et al. Among authors: hegedus b. Sci Rep. 2020 Oct 29;10(1):18677. doi: 10.1038/s41598-020-75807-x. Sci Rep. 2020. PMID: 33122816 Free PMC article.
The Prognostic Relevance of PMCA4 Expression in Melanoma: Gender Specificity and Implications for Immune Checkpoint Inhibition.
Hegedüs L, Livingstone E, Bánkfalvi Á, Viehof J, Enyedi Á, Bilecz Á, Győrffy B, Baranyi M, Tőkés AM, Gil J, Marko-Varga G, Griewank KG, Zimmer L, Váraljai R, Sucker A, Zaremba A, Schadendorf D, Aigner C, Hegedüs B. Hegedüs L, et al. Among authors: hegedus b. Int J Mol Sci. 2022 Mar 19;23(6):3324. doi: 10.3390/ijms23063324. Int J Mol Sci. 2022. PMID: 35328746 Free PMC article.
195 results